Comparison of Ro 31-8959 Plus Zidovudine (AZT) Versus AZT Plus Zalcitabine (ddC) Versus Ro 31-8959 Plus AZT Plus ddC
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
PRIMARY: To determine the efficacy and toxicity of three treatment regimens: saquinavir
mesylate (Ro 31-8959) plus zidovudine (AZT) vs. AZT plus zalcitabine (dideoxycytidine; ddC)
vs. Ro 31-8959 plus AZT plus ddC.
SECONDARY: To investigate the pharmacokinetics and effects on various clinical parameters of
the three regimens.